Venus Medtech (Hangzhou) Future Growth
Future criteria checks 2/6
Venus Medtech (Hangzhou) is forecast to grow earnings and revenue by 85.9% and 31.9% per annum respectively. EPS is expected to grow by 80.6% per annum. Return on equity is forecast to be -3.9% in 3 years.
Key information
85.9%
Earnings growth rate
80.6%
EPS growth rate
| Medical Equipment earnings growth | 39.9% |
| Revenue growth rate | 31.9% |
| Future return on equity | -3.9% |
| Analyst coverage | Good |
| Last updated | 09 Jan 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,707 | N/A | 285 | N/A | 4 |
| 12/31/2025 | 1,154 | -9 | -72 | 41 | 6 |
| 12/31/2024 | 809 | -289 | -327 | -206 | 6 |
| 12/31/2023 | 566 | -570 | -519 | -422 | 6 |
| 6/30/2023 | 452 | -1,208 | -839 | -797 | N/A |
| 3/31/2023 | 429 | -1,133 | -874 | -763 | N/A |
| 12/31/2022 | 406 | -1,058 | -908 | -729 | N/A |
| 9/30/2022 | 397 | -759 | -845 | -622 | N/A |
| 6/30/2022 | 387 | -461 | -781 | -515 | N/A |
| 3/31/2022 | 401 | -417 | -670 | -486 | N/A |
| 12/31/2021 | 416 | -374 | -559 | -457 | N/A |
| 9/30/2021 | 415 | -313 | -505 | -390 | N/A |
| 6/30/2021 | 413 | -252 | -452 | -322 | N/A |
| 3/31/2021 | 345 | -217 | -406 | -280 | N/A |
| 12/31/2020 | 276 | -182 | -361 | -237 | N/A |
| 9/30/2020 | 252 | -210 | -333 | -250 | N/A |
| 6/30/2020 | 228 | -238 | -305 | -264 | N/A |
| 3/31/2020 | 231 | -310 | -316 | -284 | N/A |
| 12/31/2019 | 233 | -381 | -328 | -303 | N/A |
| 12/31/2018 | 115 | -300 | -178 | -151 | N/A |
| 12/31/2017 | 18 | -157 | -102 | -82 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2500 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2500 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2500 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2500's revenue (31.9% per year) is forecast to grow faster than the Hong Kong market (8.6% per year).
High Growth Revenue: 2500's revenue (31.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2500 is forecast to be unprofitable in 3 years.